

Baldwin Park, CA, December 2019 –

Results for screening and detection of lung cancer from measurement of breath samples with the Cyranose 320 have been reported recently by researchers in Latvia and other countries who are working to establish low-cost, rapid and non-invasive screening tests.

Detection of lung cancer with electronic nose and logistic regression analysis.
M. Tirzite et al. Journal of Breath Research vol 13. (2019).

A total of 252 cancer patients and 223 patients without cancer were tested. The group included patients with histologically or cytologically verified, untreated lung cancer, patients with other lung diseases such as benign lung tumors, chronic obstructive pulmonary disease, asthma and pneumonia. Breath sample collection and analysis were performed with Cyranose 320 sensor device and data further analysed using LRA. The LRA correctly differentiated lung cancer patients from non-cancer patients. The overall sensitivity in detecting patients having cancer was 95.8% for smokers and 96.2% for non-smokers and the overall specificity was 90.6% for non-smokers and 92.3% for smokers.

Contact Sensigent at sales@sensigent.com for more information on the Cyranose® 320 and our other products for clinical testing.